Natural News

Germany’s CureVac coronavirus (COVID-19) vaccine has been found to be only 47 percent effective against the SARS-CoV-2, the virus behind the pandemic, dropping the company’s shares in Frankfurt and New York by more than 50 percent and erasing more than £5 billion ($6.9 billion) from its market value.

The interim results from the late-stage testing are below the minimum threshold of 50 percent efficacy set by the World Health Organization (WHO).


Similar Posts

Leave a Reply

Your email address will not be published.